3.37
0.02 (0.60%)
| Previous Close | 3.35 |
| Volume | 148,600 |
| Price / Sales | 21.61 |
| Price / Book | 2.08 |
| 52 Weeks Range |
| Profit Margin | 46.54% |
| Operating Margin (TTM) | -32.78% |
| Diluted EPS (TTM) | 2.11 |
| Total Debt/Equity (MRQ) | 340.14% |
| Current Ratio (MRQ) | 3.70 |
| Operating Cash Flow (TTM) | -109.67 M |
| Levered Free Cash Flow (TTM) | -78.01 M |
| Return on Assets (TTM) | -58.61% |
| Return on Equity (TTM) | 121.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | X4 Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Relative Valuation | NA |
| Financial Health | -5.0 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.13 |
Select this tab to load the latest available analysis.
|
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.43% |
| % Held by Institutions | 55.70% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |